Phase 1 Extension Study to Evaluate Antibody Persistence Approximately 3 Years After Administration of Different Dosages of Acellular Pertussis or Tetanus-Diphtheria-acellular Pertussis Booster Vaccines in Healthy Adult Subjects Enrolled in Study V113_01

Trial Profile

Phase 1 Extension Study to Evaluate Antibody Persistence Approximately 3 Years After Administration of Different Dosages of Acellular Pertussis or Tetanus-Diphtheria-acellular Pertussis Booster Vaccines in Healthy Adult Subjects Enrolled in Study V113_01

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Feb 2016

At a glance

  • Drugs Pertussis acellular vaccine (Primary) ; DTaP vaccine
  • Indications Diphtheria; Pertussis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors Novartis Vaccines
  • Most Recent Events

    • 30 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 25 Jun 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 22 Apr 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top